| Bradley Andrew Morganstern, | |
|
1999 Marcus Ave Ste M18, New Hyde Park, NY 11042-1023 | |
| (516) 466-6953 | |
| (516) 466-6953 |
| Full Name | Bradley Andrew Morganstern |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 13 Years |
| Location | 1999 Marcus Ave Ste M18, New Hyde Park, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558651398 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2088P0231X | Urology - Pediatric Urology | 281976 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Au Medical Center | Augusta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Au Medical Associates Inc | 9931013513 | 577 |
News Archive
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.
Despite the potential for conflict of interest, virtually all practicing physicians in the U.S. have some form of relationship with pharmaceutical manufacturers but the nature and extent of those relationships vary, depending on the kind of practice, medical specialty, patient mix, and professional activities, reports a study in the April 26 issue of the New England Journal of Medicine.
Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.
› Verified 5 days ago
| Entity Name | Au Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841230620 PECOS PAC ID: 9931013513 Enrollment ID: O20040107000188 |
News Archive
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.
Despite the potential for conflict of interest, virtually all practicing physicians in the U.S. have some form of relationship with pharmaceutical manufacturers but the nature and extent of those relationships vary, depending on the kind of practice, medical specialty, patient mix, and professional activities, reports a study in the April 26 issue of the New England Journal of Medicine.
Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.
› Verified 5 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.
Despite the potential for conflict of interest, virtually all practicing physicians in the U.S. have some form of relationship with pharmaceutical manufacturers but the nature and extent of those relationships vary, depending on the kind of practice, medical specialty, patient mix, and professional activities, reports a study in the April 26 issue of the New England Journal of Medicine.
Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bradley Andrew Morganstern, 300 Community Dr, Manhasset, NY 11030-3816 Ph: () - | Bradley Andrew Morganstern, 1999 Marcus Ave Ste M18, New Hyde Park, NY 11042-1023 Ph: (516) 466-6953 |
News Archive
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.
Armed with new grant support, investigators at Nationwide Children's Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma.
Despite the potential for conflict of interest, virtually all practicing physicians in the U.S. have some form of relationship with pharmaceutical manufacturers but the nature and extent of those relationships vary, depending on the kind of practice, medical specialty, patient mix, and professional activities, reports a study in the April 26 issue of the New England Journal of Medicine.
Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.
› Verified 5 days ago
Zeph Okeke, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 27005 76th Ave, New Hyde Park, NY 11040 Phone: 718-470-7220 Fax: 718-343-6254 | |
Dr. Robert M Moldwin, Urology Medicare: Accepting Medicare Assignments Practice Location: 27005 76th Ave, New Hyde Park, NY 11040 Phone: 718-470-7334 | |
Jessica Erin Kreshover, MD, MS Urology Medicare: Accepting Medicare Assignments Practice Location: 450 Lakeville Rd, Suite M41, New Hyde Park, NY 11042 Phone: 516-734-8500 | |
Manish A Vira, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 27005 76th Ave, New Hyde Park, NY 11040 Phone: 718-470-3900 Fax: 718-343-6254 | |
Arthur Smith, MD Urology Medicare: Medicare Enrolled Practice Location: Lijmc - Dept Of Urology, 270-05 76th Avenue, New Hyde Park, NY 11040 Phone: 718-470-7222 | |
Dr. Aaron Justin Krill, MD Urology Medicare: Medicare Enrolled Practice Location: 1999 Marcus Ave Ste M18, Department Of Pediatric Urology, New Hyde Park, NY 11042 Phone: 516-466-6953 Fax: 516-466-5608 | |
Christopher Jonathan Hartman, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 450 Lakeville Rd, Suite M41, New Hyde Park, NY 11042 Phone: 516-734-8500 |